Literature DB >> 12127202

Discriminative-stimulus effects of modafinil in cocaine-trained humans.

Craig R Rush1, Thomas H Kelly, Lon R Hays, Adam F Wooten.   

Abstract

Modafinil is a novel stimulant that is effective in the treatment of narcolepsy and excessive daytime sleepiness. In vitro and in vivo neuropharmacological data suggest that the mechanism of action of modafinil is distinct from that of prototypical abused stimulants like cocaine and d-amphetamine. In the present experiment, six human volunteers with recent histories of cocaine use learned to discriminate 150 mg oral cocaine HCL. After acquiring the discrimination (i.e. > or = 80% correct responding on 4 consecutive days), a range of doses of oral cocaine (50, 100, and 150 mg), modafinil (200, 400, and 600 mg), and placebo were tested to determine if they shared discriminative-stimulus and self-reported effects with 150 mg cocaine. Methylphenidate (60 mg) and triazolam (0.5 mg) were included as positive and negative controls, respectively. Cocaine and methylphenidate, but neither modafinil nor triazolam, produced cocaine-like discriminative-stimulus, subject-rated, and cardiovascular effects. The results of the present experiment suggest that cocaine discrimination in humans is pharmacologically specific within and across drug classes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12127202     DOI: 10.1016/s0376-8716(02)00082-0

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  31 in total

Review 1.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

Review 2.  Agonist replacement therapy for cocaine dependence: a translational review.

Authors:  Craig R Rush; William W Stoops
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

3.  Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse.

Authors:  Carmela M Reichel; Ronald E See
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

4.  Modafinil for the treatment of cocaine dependence.

Authors:  Ann L Anderson; Malcolm S Reid; Shou-Hua Li; Tyson Holmes; Lynn Shemanski; April Slee; Edwina V Smith; Roberta Kahn; Nora Chiang; Frank Vocci; Domenic Ciraulo; Charles Dackis; John D Roache; Ihsan M Salloum; Eugene Somoza; Harold C Urschel; Ahmed M Elkashef
Journal:  Drug Alcohol Depend       Date:  2009-06-26       Impact factor: 4.492

Review 5.  Approaches to measuring the effects of wake-promoting drugs: a focus on cognitive function.

Authors:  Christopher J Edgar; Edward F Pace-Schott; Keith A Wesnes
Journal:  Hum Psychopharmacol       Date:  2009-07       Impact factor: 1.672

Review 6.  Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Curr Top Behav Neurosci       Date:  2018

7.  Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.

Authors:  Neil E Paterson; Allison Fedolak; Berend Olivier; Taleen Hanania; Afshin Ghavami; Barbara Caldarone
Journal:  Pharmacol Biochem Behav       Date:  2010-03-25       Impact factor: 3.533

Review 8.  Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls.

Authors:  Margaret Haney
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

9.  Modafinil does not serve as a reinforcer in cocaine abusers.

Authors:  Suzanne K Vosburg; Carl L Hart; Margaret Haney; Eric Rubin; Richard W Foltin
Journal:  Drug Alcohol Depend       Date:  2009-09-23       Impact factor: 4.492

Review 10.  Controversies in translational research: drug self-administration.

Authors:  Margaret Haney; Roger Spealman
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.